A Phase 4 interventional study of Clindamycin and benzoyl peroxide and benzoyl peroxide 2.5% and adapalene 0.1% gel in Acne Vulgaris, sponsored by Stiefel, a GSK Company. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-05-20.
Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.
Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 24th largest by enrollment, is one of 8 that started in 2009, is one of 16 in phase 4, and was the 9th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:
Centre for Human Drug Research, Netherlands · Sites in Netherlands
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 9 · Phase 4 16
First in 2005; this study’s year is marked. 8 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 117 across the 34 interventional studies. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stiefel, a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Stiefel, a GSK Company is the lead sponsor of 56 studies on the registry; none are open to participants now.
42 studies in Acne Vulgaris by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 42 finished, 24 (57%) have results posted.
Among the 42 studies in Acne Vulgaris by GlaxoSmithKline, this one is the 24th largest by enrollment, is one of 13 that started in 2009, is one of 16 in phase 4, and was the 12th registered.
GlaxoSmithKline’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing clindamycin in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 42 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single-blind (blinded expert grader), randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, antibiotic and benzoyl peroxide or benzoyl peroxide and adapalene gel and the contra lateral side of the face will remain non-treated to serve as a control. Approximately 25-30 male and female healthy subjects will be randomly assigned to each product
This is a single-blind (blinded expert grader), parallel group, randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, a topical antibiotic and benzoyl peroxide or benzoyl peroxide and adapalene and the contra lateral side of the face will remain non-treated to serve as a control. Approximately 25-30 male and female healthy subjects will be randomly assigned to each product.
The subjects will be entered into a 2-week treatment phase. The once-daily applications for the study medication will be supervised at the site, Monday through Friday of each week. Subjects will apply the study product at home on Saturdays and Sundays.
A blinded expert grader will rate comparative product tolerance on each week day (excluding Saturdays and Sundays) during the study before study product is applied.
Subject questionnaires will be completed along with collection of all adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide (BPO).
Drug: Clindamycin and benzoyl peroxide
Once-daily applications, to the randomized side of the face either left or right, of benzoyl peroxide (BPO) and adapalene
Drug: benzoyl peroxide 2.5% and adapalene 0.1% gel
Drug pages: Clindamycin · Benzoyl Peroxide
Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
Also known as: Duac® Topical Gel (clindamycin and benzoyl peroxide.
Drug page: Benzoyl Peroxide
Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
Also known as: benzoyl peroxide gel and adapalene gel
Skin Erythema (Redness)
Assessment of erythema as part of an evaluation of tolerance of two treatments: clindamycin and benzoyl peroxide or dapsone gel. This was done by visual assessment by an independent blinded grader using the grading scale shown below. Grade Description 0 None 2 Mild erythema 4 Moderate confluent erythema 6 Marked erythema with some edema 8 Marked erythema, edema, possible erosion
Time frame: Baseline, Day 1 through Day 14
Skin Dryness
The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate skin dryness is: Grade Description 0 None 2 Slight flaking 4 Moderate flaking/scaling 6 Marked scaling / slight fissuring 8 Severe scaling, fissuring Expert Grader assessments of dryness were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
Time frame: Baseline, Day 1 through Day 14
Skin Moisture and Hydration
To assess skin moisture and hydration using transepidermal water loss (TEWL). Results are measured on a continuous scale. Higher values indicate greater water loss/ lower skin moisture levels. Evaporative water loss measurements provide an instrumental assessment of skin barrier function(one of the layers of the skin. Damage leads to a disruption of the barrier that is accompanied by elevated water loss rates and affects skin moisture and hydration. Higher values indicate greater water loss.
Time frame: Baseline, Days 3, 7, and 14
Skin Hydration
The ability of an alternating current to flow through the stratum corneum is an indirect measure of its water content. The value recorded is expressed in microsiemens. Higher values indicate greater levels of skin hydration. Test results were compared to measurements from the other side of the face, which was not treated instead of referring to a normal range. A normal range does not exist for this measurement. Instead, the non-treated side of the face was used as a control to determine the normal level of skin hydration.
Time frame: Baseline, 4 hrs. post 1st Treatment, Days 3, 7, and 14
Self Assessment of Burning
The amount of burning on the left and right cheek of each panelist. The scale used to evaluate burning is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
Time frame: Baseline, Day 1 through Day 14
Self Assessment of Stinging
The amount of stinging on the left and right cheek of each panelist. The scale used to evaluate stinging is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of stinging were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
Time frame: Baseline, Day 1 through Day 14
Self Assessment of Dryness
The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate dryness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
Time frame: Baseline, Day 1 through Day 14
Self Assessment of Texture (Roughness)
The amount of roughness on the left and right cheek of each panelist. The scale used to evaluate roughness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
Time frame: Baseline, Day 1 through Day 14
Self Assessment of Pain
The amount of pain on the left and right cheek of each panelist. The scale used to evaluate pain is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
Time frame: Baseline, Day 1 through Day 14
Self Assessment of Crusting
The amount of crusting on the left and right cheek of each panelist. The scale used to evaluate crusting is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
Time frame: Baseline, Day 1 through Day 14
Self Assessment of Blistering
The amount of blistering on the left and right cheek of each panelist. The scale used to evaluate blistering is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
Time frame: Baseline, Day 1 through Day 14
Self Assessment of Oiliness
The amount of oiliness on the left and right cheek of each panelist. The scale used to evaluate oiliness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
Time frame: Baseline, Day 1 through Day 14
Product Acceptability and Preference Questionnaire - How do You Rate the Comfort of the Skin Where You Are Currently Treating With the Study Product?
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: How do you rate the comfort of the skin where you are currently treating with the study product? The subject replied using the following scale: 1. - Very Comfortable 2. - Comfortable 3. - Somewhat Comfortable 4. - Somewhat Uncomfortable 5. - Uncomfortable
Time frame: Day 14
Product Acceptability and Preference Questionnaire - How Compliant Were You With Applying the Study Product Each and Every Day?
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: How compliant were you with applying the study product each and every day? The subject replied using the following scale: 0 - Not Compliant at all (\<50%) 1. - Mostly Compliant (50%-79%) 2. - Very Compliant (80%-100%)
Time frame: Day 14
Product Acceptability and Preference Questionnaire - Did You Feel That Your Skin Was Hydrated and Moisturized While You Were on Your Study Product?
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product? The subject replied using the following scale: 1 - Yes 0 - No
Time frame: Day 14
Product Acceptability and Preference Questionnaire - Was the Study Product Easy to Use With Make-up?
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Was the study product easy to use with make-up? The subject replied using the following scale: 0 - Not Applicable 1. - Very Easy 2. - Easy 3. - Neutral 4. - Difficult 5. - Very Difficult
Time frame: Day 14
Product Acceptability and Preference Questionnaire - What Was Your Overall Satisfaction of the Study Product?
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: What was your overall satisfaction of the study product? The subject replied using the following scale: 1. - Very Satisfied 2. - Satisfied 3. - Neutral 4. - Unsatisfied 5. - Very Unsatisfied
Time frame: Day 14
Product Acceptability and Preference Questionnaire - How do You Rate the Ease of Application of the Study Product?
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Was the study product easy to use with make-up? The subject replied using the following scale: 0 - Not Applicable 1. - Very Easy 2. - Easy 3. - Neutral 4. - Difficult 5. - Very Difficult
Time frame: Day 14
Clinical research center.
| Milestone | Duac | Epiduo |
|---|---|---|
| Started | 25 | 27 |
| Completed | 23 | 24 |
| Not completed | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Skin irritation | 1 | 2 |
Assessment of erythema as part of an evaluation of tolerance of two treatments: clindamycin and benzoyl peroxide or dapsone gel. This was done by visual assessment by an independent blinded grader using the grading scale shown below. Grade Description 0 None 2 Mild erythema 4 Moderate confluent erythema 6 Marked erythema with some edema 8 Marked erythema, edema, possible erosion
| Units on a scale | Duac | Epiduo |
|---|---|---|
| Baseline | 1.56 ± 0.92 | 1.89 ± 1.01 |
| Day 1 | 2.62 ± 1.32 | 2.65 ± 0.94 |
| Day 2 | 2.90 ± 1.23 | 2.52 ± 1.03 |
| Day 3 | 3.08 ± 1.23 | 2.81 ± 1.02 |
| Day 6 | 3.17 ± 1.33 | 3.13 ± 0.89 |
| Day 7 | 3.07 ± 1.30 | 3.08 ± 1.01 |
| Day 8 | 2.87 ± 1.24 | 2.98 ± 1.08 |
| Day 9 | 2.78 ± 1.36 | 3.03 ± 0.99 |
| Day 10 | 2.89 ± 1.22 | 2.94 ± 1.02 |
| Day 13 | 2.85 ± 1.20 | 2.83 ± 1.21 |
| Day 14 | 2.73 ± 1.20 | 2.56 ± 1.03 |
To assess skin moisture and hydration using transepidermal water loss (TEWL). Results are measured on a continuous scale. Higher values indicate greater water loss/ lower skin moisture levels. Evaporative water loss measurements provide an instrumental assessment of skin barrier function(one of the layers of the skin. Damage leads to a disruption of the barrier that is accompanied by elevated water loss rates and affects skin moisture and hydration. Higher values indicate greater water loss.
| TEWL rates (gm/m2/hr) | Duac | Epiduo |
|---|---|---|
| Baseline | 11.50 ± 3.65 | 13.07 ± 5.06 |
| Day 3 | 11.38 ± 2.49 | 15.85 ± 9.12 |
| Day 7 | 14.51 ± 3.65 | 21.65 ± 8.66 |
| Day 14 | 13.36 ± 3.33 | 19.28 ± 8.10 |
The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate skin dryness is: Grade Description 0 None 2 Slight flaking 4 Moderate flaking/scaling 6 Marked scaling / slight fissuring 8 Severe scaling, fissuring Expert Grader assessments of dryness were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
| units on a scale | Duac | Epiduo |
|---|---|---|
| Baseline | 0.12 ± 0.44 | 0.07 ± 0.27 |
| Day 1 | 0.41 ± 0.85 | 0.25 ± 0.57 |
| Day 2 | 0.32 ± 0.83 | 0.34 ± 0.59 |
| Day 3 | 0.46 ± 0.91 | 0.55 ± 1.15 |
| Day 6 | 0.61 ± 1.02 | 1.73 ± 1.76 |
| Day 7 | 0.69 ± 1.16 | 1.85 ± 2.01 |
| Day 8 | 0.60 ± 1.13 | 1.87 ± 2.04 |
| Day 9 | 0.73 ± 1.28 | 2.29 ± 1.99 |
| Day 10 | 0.56 ± 1.04 | 1.49 ± 1.77 |
| Day 13 | 0.80 ± 1.33 | 1.26 ± 1.85 |
| Day 14 | 0.79 ± 1.04 | 1.33 ± 1.75 |
The ability of an alternating current to flow through the stratum corneum is an indirect measure of its water content. The value recorded is expressed in microsiemens. Higher values indicate greater levels of skin hydration. Test results were compared to measurements from the other side of the face, which was not treated instead of referring to a normal range. A normal range does not exist for this measurement. Instead, the non-treated side of the face was used as a control to determine the normal level of skin hydration.
| Microsiemens | Duac | Epiduo |
|---|---|---|
| Baseline | 378.06 ± 131.08 | 392.09 ± 162.16 |
| 4 hrs Post 1st Treatment | 323.47 ± 154.30 | 415.90 ± 197.57 |
| Day 3 | 420.97 ± 122.60 | 465.25 ± 175.65 |
| Day 7 | 385.91 ± 156.69 | 414.77 ± 154.46 |
| Day 14 | 401.98 ± 156.08 | 418.51 ± 139.64 |
The amount of burning on the left and right cheek of each panelist. The scale used to evaluate burning is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
| units on a scale | Duac | Epiduo |
|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 1 | 0.04 ± 0.20 | 0.04 ± 0.19 |
| Day 2 | 0.04 ± 0.20 | 0.04 ± 0.19 |
| Day 3 | 0.12 ± 0.33 | 0.15 ± 0.36 |
| Day 6 | 0.12 ± 0.33 | 0.56 ± 0.85 |
| Day 7 | 0.17 ± 0.48 | 0.70 ± 0.87 |
| Day 8 | 0.17 ± 0.48 | 0.50 ± 0.81 |
| Day 9 | 0.13 ± 0.45 | 0.27 ± 0.67 |
| Day 10 | 0.13 ± 0.45 | 0.31 ± 0.68 |
| Day 13 | 0.08 ± 0.28 | 0.35 ± 0.75 |
| Day 14 | 0.08 ± 0.28 | 0.19 ± 0.57 |
The amount of stinging on the left and right cheek of each panelist. The scale used to evaluate stinging is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of stinging were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
| units on a scale | Duac | Epiduo |
|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 1 | 0.08 ± 0.28 | 0.00 ± 0.00 |
| Day 2 | 0.08 ± 0.28 | 0.00 ± 0.00 |
| Day 3 | 0.12 ± 0.44 | 0.04 ± 0.19 |
| Day 6 | 0.1 ± 0.4 | 0.4 ± 0.8 |
| Day 7 | 0.17 ± 0.48 | 0.30 ± 0.67 |
| Day 8 | 0.17 ± 0.48 | 0.35 ± 0.69 |
| Day 9 | 0.13 ± 0.45 | 0.15 ± 0.54 |
| Day 10 | 0.13 ± 0.45 | 0.12 ± 0.43 |
| Day 13 | 0.13 ± 0.34 | 0.19 ± 0.57 |
| Day 14 | 0.08 ± 0.28 | 0.12 ± 0.43 |
The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate dryness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
| units on a scale | Duac | Epiduo |
|---|---|---|
| Baseline | 0.24 ± 0.44 | 0.30 ± 0.54 |
| Day 1 | 0.2 ± 0.4 | 0.19 ± 0.40 |
| Day 2 | 0.16 ± 0.37 | 0.15 ± 0.36 |
| Day 3 | 0.24 ± 0.44 | 0.2 ± 0.4 |
| Day 6 | 0.48 ± 0.77 | 0.67 ± 0.96 |
| Day 7 | 0.54 ± 0.72 | 0.70 ± 0.91 |
| Day 8 | 0.54 ± 0.78 | 0.81 ± 1.02 |
| Day 9 | 0.54 ± 0.78 | 0.85 ± 1.01 |
| Day 10 | 0.50 ± 0.78 | 0.69 ± 0.88 |
| Day 13 | 0.50 ± 0.78 | 0.73 ± 0.96 |
| Day 14 | 0.46 ± 0.72 | 0.69 ± 1.05 |
The amount of roughness on the left and right cheek of each panelist. The scale used to evaluate roughness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
| units on a scale | Duac | Epiduo |
|---|---|---|
| Baseline | 0.28 ± 0.54 | 0.15 ± 0.36 |
| Day 1 | 0.20 ± 0.50 | 0.07 ± 0.27 |
| Day 2 | 0.16 ± 0.47 | 0.07 ± 0.27 |
| Day 3 | 0.32 ± 0.69 | 0.07 ± 0.27 |
| Day 6 | 0.28 ± 0.68 | 0.33 ± 0.78 |
| Day 7 | 0.33 ± 0.76 | 0.19 ± 0.56 |
| Day 8 | 0.25 ± 0.61 | 0.3 ± 0.7 |
| Day 9 | 0.29 ± 0.69 | 0.15 ± 0.46 |
| Day 10 | 0.29 ± 0.69 | 0.15 ± 0.46 |
| Day 13 | 0.33 ± 0.70 | 0.12 ± 0.43 |
| Day 14 | 0.29 ± 0.69 | 0.15 ± 0.46 |
The amount of pain on the left and right cheek of each panelist. The scale used to evaluate pain is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
| units on a scale | Duac | Epiduo |
|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 1 | 0.04 ± 0.20 | 0.04 ± 0.19 |
| Day 2 | 0.04 ± 0.20 | 0.00 ± 0.00 |
| Day 3 | 0.04 ± 0.20 | 0.00 ± 0.00 |
| Day 6 | 0.04 ± 0.20 | 0.1 ± 0.4 |
| Day 7 | 0.04 ± 0.20 | 0.04 ± 0.19 |
| Day 8 | 0.04 ± 0.20 | 0.04 ± 0.20 |
| Day 9 | 0.04 ± 0.20 | 0.00 ± 0.00 |
| Day 10 | 0.04 ± 0.20 | 0.00 ± 0.00 |
| Day 13 | 0.04 ± 0.20 | 0.00 ± 0.00 |
| Day 14 | 0.04 ± 0.20 | 0.00 ± 0.00 |
The amount of crusting on the left and right cheek of each panelist. The scale used to evaluate crusting is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
| units on a scale | Duac | Epiduo |
|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 1 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 2 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 3 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 6 | 0.00 ± 0.00 | 0.07 ± 0.38 |
| Day 7 | 0.00 ± 0.00 | 0.04 ± 0.19 |
| Day 8 | 0.00 ± 0.00 | 0.04 ± 0.20 |
| Day 9 | 0.00 ± 0.00 | 0.04 ± 0.20 |
| Day 10 | 0.00 ± 0.00 | 0.04 ± 0.20 |
| Day 13 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 14 | 0.00 ± 0.00 | 0.00 ± 0.00 |
The amount of blistering on the left and right cheek of each panelist. The scale used to evaluate blistering is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
| units on a scale | Duac | Epiduo |
|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 1 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 2 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 3 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 6 | 0.00 ± 0.00 | 0.07 ± 0.38 |
| Day 7 | 0.00 ± 0.00 | 0.04 ± 0.19 |
| Day 8 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 9 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 10 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 13 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 14 | 0.00 ± 0.00 | 0.00 ± 0.00 |
The amount of oiliness on the left and right cheek of each panelist. The scale used to evaluate oiliness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
| units on a scale | Duac | Epiduo |
|---|---|---|
| Baseline | 0.12 ± 0.33 | 0.19 ± 0.40 |
| Day 1 | 0.08 ± 0.28 | 0.11 ± 0.42 |
| Day 2 | 0.00 ± 0.00 | 0.04 ± 0.19 |
| Day 3 | 0.08 ± 0.28 | 0.11 ± 0.42 |
| Day 6 | 0.04 ± 0.20 | 0.04 ± 0.19 |
| Day 7 | 0.00 ± 0.00 | 0.07 ± 0.27 |
| Day 8 | 0.00 ± 0.00 | 0.04 ± 0.20 |
| Day 9 | 0.00 ± 0.00 | 0.08 ± 0.27 |
| Day 10 | 0.00 ± 0.00 | 0.0 ± 0.2 |
| Day 13 | 0.00 ± 0.00 | 0.12 ± 0.43 |
| Day 14 | 0.00 ± 0.00 | 0.08 ± 0.27 |
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: How do you rate the comfort of the skin where you are currently treating with the study product? The subject replied using the following scale: 1. - Very Comfortable 2. - Comfortable 3. - Somewhat Comfortable 4. - Somewhat Uncomfortable 5. - Uncomfortable
| units on a scale | Duac | Epiduo |
|---|---|---|
| Product Acceptability and Preference Questionnaire - How do You Rate the Comfort of the Skin Where You Are Currently Treating With the Study Product? | 2.38 ± 1.13 | 2.23 ± 1.24 |
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: How compliant were you with applying the study product each and every day? The subject replied using the following scale: 0 - Not Compliant at all (\<50%) 1. - Mostly Compliant (50%-79%) 2. - Very Compliant (80%-100%)
| units on a scale | Duac | Epiduo |
|---|---|---|
| Product Acceptability and Preference Questionnaire - How Compliant Were You With Applying the Study Product Each and Every Day? | 2.00 ± 0.00 | 2.00 ± 0.00 |
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product? The subject replied using the following scale: 1 - Yes 0 - No
| units on a scale | Duac | Epiduo |
|---|---|---|
| Product Acceptability and Preference Questionnaire - Did You Feel That Your Skin Was Hydrated and Moisturized While You Were on Your Study Product? | 0.58 ± 0.50 | 0.54 ± 0.51 |
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Was the study product easy to use with make-up? The subject replied using the following scale: 0 - Not Applicable 1. - Very Easy 2. - Easy 3. - Neutral 4. - Difficult 5. - Very Difficult
| units on a scale | Duac | Epiduo |
|---|---|---|
| Product Acceptability and Preference Questionnaire - Was the Study Product Easy to Use With Make-up? | 1.04 ± 1.12 | 1.46 ± 1.14 |
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: What was your overall satisfaction of the study product? The subject replied using the following scale: 1. - Very Satisfied 2. - Satisfied 3. - Neutral 4. - Unsatisfied 5. - Very Unsatisfied
| units on a scale | Duac | Epiduo |
|---|---|---|
| Product Acceptability and Preference Questionnaire - What Was Your Overall Satisfaction of the Study Product? | 2.29 ± 1.04 | 2.46 ± 1.03 |
The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Was the study product easy to use with make-up? The subject replied using the following scale: 0 - Not Applicable 1. - Very Easy 2. - Easy 3. - Neutral 4. - Difficult 5. - Very Difficult
| units on a scale | Duac | Epiduo |
|---|---|---|
| Product Acceptability and Preference Questionnaire - How do You Rate the Ease of Application of the Study Product? | 1.17 ± 0.38 | 1.00 ± 0.00 |
Collected over 14 days. Non-serious events are listed at a 0.1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Duac | — | 0/25 (0%) | 13/25 (52%) |
| Epiduo | — | 0/27 (0%) | 13/27 (48.1%) |
| Event | Duac | Epiduo |
|---|---|---|
| HeadacheNervous system disorders | 4/25 | 5/27 |
| InsomniaPsychiatric disorders | 3/25 | 0/27 |
| Menstrual crampsMusculoskeletal and connective tissue disorders | 3/25 | 2/27 |
| Sore throatGeneral disorders | 2/25 | 3/27 |
| EaracheInfections and infestations | 0/25 | 3/27 |
| IrritationSkin and subcutaneous tissue disorders | 2/25 | 2/27 |
| Upper respiratory tract infectionInfections and infestations | 2/25 | 0/27 |
| ToothacheGeneral disorders | 2/25 | 1/27 |
| Joint stiffnessMusculoskeletal and connective tissue disorders | 0/25 | 2/27 |
| Seaonal allergiesInfections and infestations | 1/25 | 0/27 |
| Age, Categorical(Participants) | Duac | Epiduo | Total |
|---|---|---|---|
| <=18 years | 1 | 1 | 2 |
| Between 18 and 65 years | 24 | 26 | 50 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Duac | Epiduo | Total |
|---|---|---|---|
| Female | 23 | 26 | 49 |
| Male | 2 | 1 | 3 |
| Region of Enrollment(participants) | Duac | Epiduo | Total |
|---|---|---|---|
| United States | 25 | 27 | 52 |
The record gives a start of May 2009, a primary completion of Jun 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide